TABLE 3

Type II binding of triazole drugs by CaLDM, CgLDM and ScLDMa

Sample and azoleΔAmax[Azole]0.5 (μM)Hill numberKDH (μM)
CaLDM6×His
    PCZ0.0465 ± 0.00210.609 ± 0.0452.00 ± 0.310.37 ± 0.09
    ITC0.0432 ± 0.00270.586 ± 0.0451.95 ± 0.310.33 ± 0.09
    VCZ0.0447 ± 0.00150.510 ± 0.0291.84 ± 0.170.29 ± 0.06
    FLC0.0338 ± 0.00280.456 ± 0.0491.82 ± 0.270.24 ± 0.09
CgLDM6×His
    PCZ0.0447 ± 0.00160.444 ± 0.0272.21 ± 0.290.17 ± 0.05
    ITC0.0381 ± 0.00080.389 ± 0.0172.31 ± 0.240.11 ± 0.03
    VCZ0.0450 ± 0.00080.392 ± 0.0132.17 ± 0.160.13 ± 0.02
    FLC0.0554 ± 0.00321.028 ± 0.0861.72 ± 0.151.05 ± 0.15
ScLDM6×His
    PCZ0.044 ± 0.0140.340 ± 0.0421.90 ± 0.420.14 ± 0.09
    ITC0.037 ± 0.0100.343 ± 0.0561.70 ± 0.080.16 ± 0.03
    VCZ0.043 ± 0.0110.315 ± 0.1202.35 ± 0.490.07 ± 0.02
    FLC0.047 ± 0.0030.387 ± 0.1012.20 ± 0.760.14 ± 0.07
  • a Measurements of ΔAmax were between 429 ± 0.5 nm and 411.5 ± 1 nm. K1/2, concentration of drug giving half-maximal ΔAmax; KDH, affinity constant determined using the Hill equation. The errors are standard deviations from at least 2 separate experiments.